Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00708
|
|||||
| Drug Name |
Roxithromycin
|
|||||
| Synonyms |
9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin; 9-[O-(2-methoxyethoxymethyl)-oxime] of erythromycin; Assoral; Biaxsig (TN); Coroxin (TN); Erythromycin 9-(-O-[2-methoxyethoxy]methyloxime);Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime); Overall; RC2952; RU 28965; RU 965; RU-28965; RU-965; RXM; Rossitrol; Roxar (TN); Roximycin (TN); Roxithromycin & Tumor Necrosis Factor; Roxithromycin (JP15/USAN/INN); Roxithromycin [USAN:INN:JAN]; Roxithromycine; Roxithromycine [French]; Roxithromycinum; Roxithromycinum [Latin]; Roxitromicina; Roxitromicina [Spanish]; Roxl-150 (TN); Roxo (TN); Rulid; Rulide; Rulide (TN); Surlid; Surlid (TN); Tirabicin (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Withdrawn | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C41H76N2O15
|
|||||
| Canonical SMILES |
CCC1C(C(C(C(=NOCOCCOC)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O
|
|||||
| InChI |
InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1
|
|||||
| InChIKey |
RXZBMPWDPOLZGW-XMRMVWPWSA-N
|
|||||
| CAS Number |
CAS 80214-83-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 837 | Topological Polar Surface Area | 217 | ||
| Heavy Atom Count | 58 | Rotatable Bond Count | 13 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 17 | |||
| XLogP |
3.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
104240364
, 114784612
, 124637170
, 135013062
, 137003693
, 137241413
, 144075595
, 14791576
, 14816129
, 152109149
, 162107641
, 17193218
, 176251435
, 179038902
, 179113863
, 210279582
, 210281905
, 226447059
, 252401199
, 26612461
, 26681158
, 43527885
, 46507676
, 47500552
, 48020029
, 48020030
, 49658614
, 49658887
, 49835235
, 50123162
, 50599965
, 53787485
, 56314318
, 57288831
, 57371618
, 585237
, 602768
, 7848773
, 7890303
, 81093210
, 8149971
, 88283688
, 92124863
, 92307881
, 99301470
|
|||||
| ChEBI ID |
ChEBI:48935
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. (familyId=1465) | |||||
| 2 | Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.